Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510, 520, 522, 524, 529, 556, and 558
[Docket No. FDA-2023-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule; technical amendments.
 SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during October, November, and December 2023. The animal drug regulations are also being amended to improve their accuracy and readability.
 DATES: This rule is effective February 27, 2024.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, 
                        *george.haibel@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: I. Approvals FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during October, November, and December 2023, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOIA Summaries) under the Freedom of Information Act (FOIA). These documents, along with marketing exclusivity and patent information, may be obtained at Animal Drugs @FDA: 
                    *https://animaldrugsatfda.fda.gov/​adafda/​views/​#/​search.* Table 1—Original and Supplemental NADAs and ANADAs Approved During October, November, and December 2023 Requiring Evidence of Safety and/or Effectiveness
Date of approval
File No.
Sponsor
                             (drug labeler code)
Product name
Effect of the
                             action
21 CFR sectionOctober 11, 2023
141-572
Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 (051311)
AYRADIA (metronidazole) oral solution
Original approval for the treatment of 
                            *Giardia duodenalis*
                             infection in dogs
520.1425October 13, 2023
141-336
ECO LLC, 344 Nassau St., Princeton, NJ 08540 (066916)
AIVLOSIN (tylvalosin tartrate) Water Soluble Granules
Supplemental approval adding females intended for breeding to approved classes of swine
520.2645October 20, 2023
141-564
Pharmgate Inc., 1800 Sir Tyler Rd., Wilmington, NC 28405 (069254)
PENNCHLOR (chlortetracycline Type A medicated article) and RUMENSIN (monensin Type A medicated article)
Original approval for treatment of bacterial enteritis and pneumonia; and for increased rate of weight gain or prevention and control of coccidiosis in replacement beef and dairy heifers
558.128November 8, 2023
200-758
Felix Pharmaceuticals Pvt. Ltd., 25-28 North Wall Quay, Dublin 1, Ireland (086101)
Enrofloxacin Injectable Solution
Original approval for treatment and control of bovine respiratory disease (BRD) in beef cattle and non-lactating dairy cattle and swine respiratory disease (SRD) and control of colibacillosis in groups or pens of weaned pigs, as a generic copy of NADA 141-068
522.812( print page 14408)November 17, 2023
141-580
Orion Corp., Orionintie 1, 02200 Espoo, Finland (052483)
BONQAT (pregabalin) Oral Solution
Original approval for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats
520.1892December 14, 2023
141-502
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 (054771)
REVOLUTION PLUS (selamectin and sarolaner topical solution)
Supplemental approval for the treatment and control of tick infestations with 
                            *Amblyomma americanum*
                             (lone star tick) in cats and kittens 8 weeks of age and older, and weighing 2.8 pounds or greater
524.2099December 21, 2023
200-760
Cronus Pharma Specialties India Private Ltd., Sy No-99/1, M/s GMR Hyderabad Aviation SEZ Ltd., Mamidipalli Village, Shamshabad Mandal, Ranga Reddy, Hyderabad, Telangana, 501218, India (069043)
FLORFENIJECT (florfenicol) Injectable Solution
Original approval for treatment of bovine respiratory disease (BRD) and bovine interdigital phlegmon; and for the control of respiratory disease in cattle at high risk of developing BRD, as a generic copy of NADA 141-063
522.955December 22, 2023
200-762
Do
CAROFENVET (carprofen) Injectable Solution
Original approval for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries, as a generic copy of NADA 141-199
522.304December 22, 2023
200-764
Do
ENROPRO 22.7 (enrofloxacin) Injectable Solution
Original approval for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin, as a generic copy of NADA 140-913
522.812December 22, 2023
200-765
Do
ENROPRO 100 (enrofloxacin) Injectable Solution
Original approval for treatment and control of bovine respiratory disease (BRD) in beef cattle and non-lactating dairy cattle and swine respiratory disease (SRD) and control of colibacillosis in groups or pens of weaned pigs, as a generic copy of NADA 141-068
522.812
 II. Withdrawals of Approval ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305-3115 (drug labeler code 012286) requested that FDA withdraw approval of the four NADAs listed in table 2 because the products are no longer manufactured or marketed. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these actions. Table 2—Applications for Which Approval Was Voluntarily Withdrawn During October, November, and December 2023
Date of withdrawal
                             of approval
File No.
New animal drug
21 CFR
                             sectionNovember 14, 2023
030-578
E-Z-EX Wormer Pellets (thiabendazole)
n/aDo
042-910
E-Z-EX WORMER MINTRATE Block (thiabendazole) Mineral Protein Block
558.600Do
118-877
BAN-A-WORM (pyrantel tartrate) Ton Pack
n/aDo
132-448
FLAVOMYCIN (bambermycins) Type A Medicated Article
558.95
 III. Change of Sponsor The sponsors of the approved applications listed in table 3 have informed FDA that they have transferred ownership of, and all rights and interest in, these applications to another sponsor. The regulations cited in table 3 are amended to reflect these actions. Table 3—Applications for Which Ownership Was Transferred to Another Sponsor During October, November, and December 2023
File No.
Product name
Transferring sponsor
                             (drug labeler code)
New sponsor
                             (drug labeler code)
21 CFR
                             section200-237
Isoflurane, U.S.P
Piramal Pharma Ltd., Ground Floor, Piramal Ananta, Agastya Corporate Park, Mumbai, Maharashtra, 400070, India (065085)
Piramal Critical Care, Inc., 3850 Schelden Circle, Bethlehem, PA 18017 (066794)
529.1186( print page 14409)200-576
Gentamicin Sulfate Ophthalmic Solution
Akorn Operating Co. LLC, 5605 Centerpoint Ct., Suite A, Gurnee, IL 60031 (059399)
Domes Pharma S.A., ZAC de Champ Lamet, 3 rue Andre Citroen, Pont-du-Chateau, Auvergne-Rhône-Alpes, 63430, France (086189)
524.1044a200-670
SENERGY (selamectin) Topical Solution
Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, County Galway, Ireland (061651)
Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 (051311)
524.2098200-700
PARASEDGE Multi for Dogs (Imidacloprid and moxidectin)
Do
Do
524.1146200-701
PARASEDGE Multi for Cats (Imidacloprid and moxidectin)
Do
Do
524.1146
 IV. Change of Sponsor Address Accord Healthcare, Inc. 1009 Slater Rd., Suite 210-B, Durham, NC 27703 (drug labeler code 016729 in 21 CFR 510.600(c)) has informed FDA that it has changed its address to 126 E Lincoln Ave., Rahway, NJ 07065. The entries in § 510.600(c) are amended to reflect this action. V. Technical Amendments FDA is making the following amendments to improve the accuracy of the animal drug regulations. 21 CFR 520.1408 is revised to reflect all approved strengths of methylprednisolone tablets for dogs and cats.
                21 CFR 556.730 is removed because there are no approved products containing thiabendazole for use in food-producing animals.
                21 CFR 558.4(d) is being revised in the Category II table by removing the row entry for “Thiabendazole” because there are no longer any approved feed products for use in food-producing animals.
                21 CFR 558.128 is revised to reflect withdrawal periods for different applications approved for use of chlortetracycline in cattle feed. VI. Legal Authority This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(i)). Although deemed a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability” and is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866. List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, 524, and 529 Animal drugs 21 CFR Part 556 Animal drugs
Food 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 520, 522, 524, 529, 556, and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.The authority citation for part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.In § 510.600, in the table in paragraph (c)(1), revise the entry for “Accord Healthcare, Inc.”; and in the table in paragraph (c)(2), revise the entry for “016729” to read as follows: § 510.600
  
 (c) * * * (1) * * * Firm name and address
Drug labeler
                                     code*         *         *         *         *         *         *Accord Healthcare, Inc., 126 E Lincoln Ave., Rahway, NJ 07065
016729*         *         *         *         *         *         *
 (2) * * * Drug labeler code
Firm name and address*         *         *         *         *         *         *016729
Accord Healthcare, Inc., 126 E Lincoln Ave., Rahway, NJ 07065.*         *         *         *         *         *         *
 PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 3.The authority citation for part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. 4.In § 520.1408, revise paragraph (b) to read as follows: § 520.1408
  
 (b) 
                            *Sponsors.*
                             See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
 5.Add § 520.1425 to read as follows: § 520.1425
  (a) 
                            *Specifications.*
                             Each milliliter of suspension contains 125 milligrams (mg) metronidazole. (b) 
                            *Sponsor.*
                             See No. 051311 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Amount.*
                             Administer 25 mg per kilogram (11.3 mg per pound) of body weight twice daily for 5 consecutive days. (2) 
                            *Indications for use.*
                             For the treatment of 
                            *Giardia duodenalis*
                             infection in dogs. (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 6.Add § 520.1892 to read as follows: § 520.1892
  (a) 
                            *Specifications.*
                             Each milliliter (mL) of solution contains 50 milligrams (mg) pregabalin. (b) 
                            *Sponsor.*
                             See No. 052483 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use*
                            —(1) 
                            *Amount.*
                             Administer orally as a single dose of 5 mg/kg (0.1 mL/kg) approximately 1.5 hours before the start of the transportation or veterinary visit. (2) 
                            *Indications for use.*
                             For alleviation of acute anxiety and fear associated with transportation and veterinary visits. (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 7.In § 520.2645, revise paragraph (d)(2) to read as follows: § 520.2645
  
 (d) * * * (2) 
                            *Indications for use.*
                             For control of porcine proliferative enteropathy (PPE) associated with 
                            *Lawsonia intracellularis*
                             infection in groups of swine intended for slaughter and female swine intended for breeding in buildings experiencing an outbreak of PPE; and for control of swine respiratory disease (SRD) associated with 
                            *Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida,**Streptococcus suis,*
                             and 
                            *Mycoplasma hyopneumoniae*
                             in groups of swine intended for slaughter and female swine intended for breeding in buildings experiencing an outbreak of SRD.
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 8.The authority citation for part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. 9.In § 522.304, revise paragraph (b) to read as follows: § 522.304
  
 (b) 
                            *Sponsors.*
                             See Nos. 016729, 017033, 054771, 055529, and 069043 in § 510.600(c) of this chapter.
 10.In § 522.812, revise paragraphs (b)(1) and (2) to read as follows: § 522.812
  
 (b) * * * (1) Nos. 016729, 017033, 055529, 058198, 069043, and 086101 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section; and (2) Nos. 051311, 055529, 058005, 058198, 061133, 069043, and 086101 for use of product described in paragraph (a)(2) as in paragraphs (e)(2) and (3) of this section.
 11.In § 522.955, revise paragraph (b)(3) and the second sentence in paragraph (d)(1)(ii)(C) to read as follows: § 522.955
  
 (b) * * * (3) Nos. 058005, 058198, and 069043 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(1)(ii) of this section. 
 (d) * * * (1) * * * (ii) * * * (C) 
                            *Limitations.*
                             * * * Nos. 000061, 058005, 058198, and 069043: Animals intended for human consumption must not be slaughtered within 38 days of subcutaneous treatment. * * *
 PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 12.The authority citation for part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. 13.In 524.1044a, revise paragraph (b) to read as follows: § 524.1044a
  
 (b) 
                            *Sponsors.*
                             See Nos. 000061 and 086189 in § 510.600(c) of this chapter.
 14.In 524.1146, revise paragraphs (b)(1) and (2) to read as follows: § 524.1146
  
 (b) * * * (1) Nos. 017030, 051072, 051311, 055529, and 058198 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section. (2) Nos. 017030, 051072, 051311, 055529, and 058198 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
 15.In 524.2098, revise paragraph (b) to read as follows: § 524.2098
  
 (b) 
                            *Sponsors.*
                             See Nos. 051072, 051311, 054771, 055529, and 061133 in § 510.600(c) of this chapter.
 16.In 524.2099, revise paragraph (c)(2) to read as follows: § 524.2099
  
 (c) * * * (2) 
                            *Indications for use.*
                             For the prevention of heartworm disease caused by 
                            *Dirofilaria immitis.*
                             Kills adult fleas (
                            *Ctenocephalides felis*) and is indicated for the treatment and prevention of flea infestations; the treatment and control of tick infestations with 
                            *Amblyomma americanum*
                             (lone star tick), 
                            *Amblyomma maculatum*
                             (Gulf Coast tick), 
                            *Dermacentor variabilis*
                             (American dog tick), and 
                            *Ixodes scapularis*
                             (black-legged tick), the treatment and control of ear mite (
                            *Otodectes cynotis*) infestations; and the treatment and control of roundworm (
                            *Toxocara cati*) and intestinal hookworm (
                            *Ancylostoma tubaeforme*) infections in cats and kittens 8 weeks of age and older, and weighing 2.8 pounds or greater.
 PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
 17.The authority citation for part 529 continues to read as follows: ( print page 14411)
                        Authority:
                        21 U.S.C. 360b. 18.In § 529.1186, revise paragraph (b) to read as follows: § 529.1186
  
 (b) 
                            *Sponsors.*
                             See Nos. 017033, 054771, and 066794 in § 510.600(c) of this chapter.
 PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 19.The authority citation for part 556 continues to read as follows: Authority:
                        21 U.S.C. 342, 360b, 371. § 556.730
 20.Remove § 556.730. PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 21.The authority citation for part 558 continues to read as follows: Authority:
                        21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371. § 558.4
 22.Amend § 558.4, by removing the entry for “Thiabendazole” in the Category II” table in paragraph (d). 23.In § 558.95, revise paragraphs (b), (e)(2)(i) and (ii), and (e)(3)(i) and (ii) to read as follows: § 558.95
  
 (b) 
                            *Sponsor.*
                             See No. 016592 in § 510.600(c) of this chapter. 
 (e) * * * (2) * * * Bambermycins in grams/ton
Indications for use
Limitations
Sponsor(i) 1 to 2
Growing turkeys: For improved feed efficiency
Feed continuously as the sole ration
016592(ii) 2
Growing turkeys: For increased rate of weight gain and improved feed efficiency
Feed continuously as the sole ration
016592
 (3) * * * Bambermycins in grams/ton
Indications for use
Limitations
Sponsor(i) 2
Growing-finishing swine: For increased rate of weight gain and improved feed efficiency
Feed continuously as the sole ration
016592(ii) 2 to 4
Growing-finishing swine: For improved feed efficiency
Feed continuously as the sole ration
016592
 24.In § 558.128: a.Revise paragraphs (e)(4)(xvi) and (xvii); b.Redesignate paragraphs (e)(4)(xxi) through (lviii) as paragraphs (e)(4)(xxiii) through (lx); and c.Add new paragraphs (e)(4)(xxi) and (xxii). The revision and additions read as follows: § 558.128
  
 (e) * * * (4) * * * Chlortetracycline amount
Combination in grams/ton
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(xvi) to provide 10 mg/lb of body weight daily

Calves, beef and nonlactating dairy cattle: For treatment of bacterial enteritis caused by 
                                    *Escherichia coli*
                                     and bacterial pneumonia caused by 
                                    *Pasteurella multocida*
                                     organisms susceptible to chlortetracycline
Feed approximately 400 g/ton, varying with body weight and feed consumption to provide 10 mg/lb per day. Treat for not more than 5 days. To sponsor No. 054771 (NADAs 048-761 and 046-699) and to sponsor No. 069254 (ANADA 200-510): May be mixed in the cattle's daily ration or administered as a top-dress. In feed including milk replacers withdraw 10 days prior to slaughter. To sponsor No. 054771 under NADA 046-699: 24-hour withdrawal period. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: Zero withdrawal period. See paragraph (d)(3) of this section
054771
                                     066104 
                                     069254(xvii) to provide 10 mg/lb of body weight daily

Calves (up to 250 lb): For the treatment of bacterial enteritis caused by Escherichia coli susceptible to chlortetracycline
A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal
066104( print page 14412)*         *         *         *         *         *         *(xxi) 400 to 2,000 g/ton
Monensin, 15 to 84
Replacement beef and dairy heifers: For treatment of bacterial enteritis caused by 
                                    *Escherichia coli*
                                     and bacterial pneumonia caused by 
                                    *Pasteurella multocida*
                                     susceptible to chlortetracycline; and for the prevention and control of coccidiosis caused by 
                                    *Eimeria bovis*
                                     and 
                                    *Eimeria zuernii*
For replacement beef and dairy heifers not currently being fed monensin: Feed as the sole ration for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day and 0.14 to 0.42 mg monensin per pound of body weight per day, depending upon severity of challenge, to provide 50 to 100 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed. After 5 days, continue to feed monensin Type C medicated feed alone to provide 50 to 200 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed
                                     For replacement beef and dairy heifers currently being fed monensin: Feed as the sole ration for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day and 0.14 to 0.42 mg monensin per pound of body weight per day, depending upon severity of challenge, to provide 50 to 200 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed. After 5 days, continue to feed monensin Type C medicated feed alone
069254This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for vealMonensin as provided by No. 058198, chlortetracycline by No. 069254 in § 510.600(c) of this chapter(xxii) 400 to 2,000 g/ton
Monensin, 15 to 400
Replacement beef and dairy heifers: For treatment of bacterial enteritis caused by 
                                    *Escherichia coli*
                                     and bacterial pneumonia caused by 
                                    *Pasteurella multocida*
                                     susceptible to chlortetracycline; and for increased rate of weight gain
For replacement beef and dairy heifers not currently being fed monensin: Feed as the sole ration for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day and 50 to 100 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed. After 5 days, continue to feed monensin Type C medicated feed alone to provide 50 to 200 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed
                                     For replacement beef and dairy heifers currently being fed monensin: Feed as the sole ration for not more than 5 days to provide 10 mg chlortetracycline per pound of body weight per day and 50 to 200 mg monensin per head per day in a minimum of 1 pound of Type C medicated feed. After 5 days, continue to feed monensin Type C medicated feed alone
069254This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for vealMonensin as provided by No. 058198, chlortetracycline by No. 069254 in § 510.600(c) of this chapter*         *         *         *         *         *         *
 § 558.600
 25.Remove § 558.600. Dated: February 20, 2024. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2024-03765 Filed 2-26-24; 8:45 am] BILLING CODE 4164-01-P